![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Propanc Biopharma, Inc. is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from solid tumors, such as pancreatic, ovarian and colorectal cancers. The Company's novel proe... Propanc Biopharma, Inc. is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from solid tumors, such as pancreatic, ovarian and colorectal cancers. The Company's novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body's primary defense against cancer. Show more
This biopharma is developing novel cancer treatments for patients suffering from recurring and metastatic cancer. Shares were trading up after the firm announced that a Certificate of Grant for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.00015 | -15.7894736842 | 0.00095 | 0.001 | 0.0007 | 20970903 | 0.00080195 | CS |
4 | -0.0006 | -42.8571428571 | 0.0014 | 0.0018 | 0.0007 | 26590357 | 0.00116135 | CS |
12 | -0.00035 | -30.4347826087 | 0.00115 | 0.0037 | 0.0006 | 27220152 | 0.00137081 | CS |
26 | -0.0094 | -92.1568627451 | 0.0102 | 0.0102 | 0.0006 | 14497815 | 0.00160726 | CS |
52 | -0.0892 | -99.1111111111 | 0.09 | 0.1222 | 0.0006 | 7623760 | 0.00263886 | CS |
156 | -41.9992 | -99.9980952381 | 42 | 52 | 0.0006 | 18578627 | 1.3303752 | CS |
260 | -1609.9992 | -99.9999503106 | 1610 | 2570 | 0.0006 | 13482449 | 2.33279901 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions